scholarly journals 633 Incorporating checkpoint inhibitors into cancer care: a study of the impact of digital education on clinical competence and practice patterns

2021 ◽  
Vol 9 (Suppl 3) ◽  
pp. A663-A663
Author(s):  
Tariqa Ackbarali ◽  
Elizabeth del Nido ◽  
Brian Rini ◽  
Michael Overman ◽  
Ignacio Witsuba
Keyword(s):  
Adverse Event ◽  
Positive Impact ◽  
Checkpoint Inhibitors ◽  
Survivorship Care ◽  
Event Management ◽  
Adverse Event Management ◽  
Biomarker Testing ◽  
Patient Prognosis ◽  
Behavioral Impact

BackgroundImmune checkpoint inhibitors have transformed the treatment landscape for a variety of tumors and have significantly improved patient prognosis and longevity. Evolving practice standards for diagnostic testing and extensive emerging clinical trial data have left clinicians challenged to apply newer treatments in practice and manage associated side effects. Additionally, improved patient prognosis has created a greater need for survivorship care plans; clinicians must be able to tailor plans to the needs of patients treated with these agents. Education pertaining to biomarker testing, applications of checkpoint inhibitors, adverse event management, and survivorship care is critical to ability to improve patient experience and quality of life.MethodsA 4-hour CME activity was broadcast live-online in June, July, and August 2020 and remained on-demand through February 2021 at OMedLive.com. The program was provided in partnership with the Society for Immunotherapy in Cancer (SITC). The initiative was divided into themes including biomarker usage for checkpoint inhibitor selection, adverse event management, survivorship care, and use of checkpoint inhibitors and combination therapies in the metastatic setting. Knowledge and competence questions were administered pre-, immediate post-, and 2 mos. post-activity. Behavioral impact questions were also asked at follow-up. Data from these questions were analyzed to determine engagement and clinical impact.ResultsFinal program results from 1,909 learners showed that post-activity engagement resulted in 61% reporting a positive impact on patient experience, and 74% reporting a positive impact on clinical practice, with 179 qualitative write-in examples detailing improvements in diagnosis, use of newer therapies, ability to manage adverse events, and patients' tolerance of treatments. All 14 CME test questions reflected statistically significant improvements on biomarker utility, checkpoint inhibitors, combination therapy applications, adverse event management, and survivorship care, with an average of 15% pre to 2-month follow-up improvement. The overall average effect size from pre- to post-test was d = 1.27, and d = 0.429 for pre- to 2-month follow-up point. Practice pattern questions elucidated preferences for biomarker testing, challenges of integrating immunotherapy, areas of difficulty in survivorship care, and challenges enrolling in clinical trials.ConclusionsThe activity was successful in improving clinician understanding of the use of biomarker testing to determine treatment plans, applications of checkpoint inhibitors and combination therapies, adverse event management, and survivorship care planning. Open-ended responses to behavioral impact questions illustrated clear improvements in clinician-reported patient impacts, including improved psychological tolerance of treatment, quality of life, and overall wellness.

Applying treatment advances in castration-resistant prostate cancer: The influence of serial digital education on the uro-oncology team.

2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 20-20
Author(s):  
Tariqa Ackbarali ◽  
Wendy Turell ◽  
Elizabeth L. del Nido ◽  
Neal D. Shore
Keyword(s):  
Prostate Cancer ◽  
Adverse Event ◽  
Treatment Options ◽  
Parp Inhibitors ◽  
Castration Resistant Prostate Cancer ◽  
Event Management ◽  
Castration Resistant ◽  
Adverse Event Management ◽  
Biomarker Testing ◽  
Behavioral Impact

20 Background: Improvements in the understanding of prostate tumor development have spurred advances in biomarker testing and new therapies for prostate cancer, providing clinicians with expanded testing and treatment options. However, these changes have led to competence gaps regarding the use of biomarker testing, integration of PARP inhibitors, application of new data for nmCRPC and mCRPC, and adverse event management. To address these needs, a serial educational initiative was designed for the urology-oncology team. Methods: A 4-part CE activity was launched live-online in December, 2020, and remains on-demand through December, 2021 at UroCareLive.com and OMedLive.com. The activity was launched in partnership with Large Urology Group Practice Association (LUGPA) and included case presentations, live polling, and Q&A. Knowledge and competence questions were administered pre-activity, immediate post-activity, and 2-months post-activity. Patient and clinical practice-impact questions were also asked at the 2-month follow-up. Data from these questions were analyzed to determine engagement and clinical impact. Results: To date, 761 clinicians have participated in the activity. All 12 CE test questions reflected improvements in knowledge and competence, 11 of which were statistically significant. Questions focused on: genomic testing, biomarker analysis, recent clinical trial study results, newly approved therapies, and adverse event management. At 2-mos. follow-up, 70% reported improved behavioral impact on clinical practice and 63% reported impact on patient experience and outcomes. Clinicians provided write-in examples of these changes, illustrating improvements in patient-reported satisfaction, genetic testing, and use of newer therapies, including PARP inhibitors. Practice pattern questions pertaining to biomarker testing and the use of emerging therapies showed the majority of post-program respondents (42%) preferred to utilize blood/serum-based biomarker tests for their patient vs urine- or tissue-based tests. The greatest reported challenges to biomarker testing were affordability (30%) and lack of guideline clarity (23%). The top 2 barriers to adoption of new agents were reported as lack of awareness and lack of experience (32% and 20%, respectively). Conclusions: The activity successfully improved uro-oncology team knowledge of genetic testing and newer therapies to manage castration-resistant prostate cancer. Learners demonstrated significant improvements in competence concerning biomarker testing, treatment personalization, and adverse event management. Open-ended responses to behavioral impact questions illustrated improvements in biomarker usage, application of newer therapies, and confidence in patient counseling regarding treatment options.

scholarly journals Value of clinical trial narrative data to estimate the costs of adverse event management: a feasibility study

2019 ◽  
Vol 23 (3) ◽  
pp. 213-220
Author(s):  
Deirdre Mladsi ◽  
Lisa M. Hess ◽  
Christine L. Barnett ◽  
Annete Njue ◽  
Yu-Jing Huang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Adverse Event ◽  
Feasibility Study ◽  
Event Management ◽  
Adverse Event Management

scholarly journals Falls in an acute care hospital as reported in the adverse event management system

2015 ◽  
Vol 4 (4) ◽  
pp. 84 ◽  
Author(s):  
Barbara J. Watson ◽  
Alan W. Salmoni ◽  
Aleksandra A. Zecevic
Keyword(s):  
Adverse Event ◽  
Acute Care ◽  
Management System ◽  
Acute Care Hospital ◽  
Time Of Day ◽  
Incident Reporting ◽  
Future Research ◽  
Care Hospital ◽  
Event Management ◽  
Adverse Event Management

Background: The increasing number of falls in hospitals precipitates the need to collect and analyze falls data. Hospital falls data have been captured through staff documentation and incident reporting systems. Objective: The purpose of this study was to identify the variables associated with falls and injurious falls in an acute care hospital over the five years from the implementation of the Adverse Event Management System (AEMS). A secondary purpose was to identify problems associated with the AEMS.Methods: Falls data recorded in the AEMS system from February 2009 to February 2014 were analyzed to observe trends of falls and contributing factors occurring in various hospital units.Results: A total of 7,721 falls occurred during the study period. The highest frequency of the falls (901) occurred between 10:00 a.m. and 12:00 p.m. There were 2,275 falls which resulted in an injury. Both total fall and injurious fall rates were highest in Medicine inpatient units and lowest in Ambulatory outpatient units. The falls rate was 4.5 falls per 1,000 patient days in 2009 and 4.4 falls per 1,000 patient days in 2014. The prevalence of falls varied among nursing unit types and the time of day but the fall rate across the hospital did not change over the five year period.Conclusions: Continuous evaluation of falls data and improved staff education is recommended to help reduce falls in acute care hospitals. A province-wide database registry should be considered for future research on incident reporting.

Reporting adverse events at geriatric facilities

2014 ◽  
Vol 27 (2) ◽  
pp. 91-98 ◽  
Author(s):  
Tali Shmueli ◽  
Ronit Har Noy ◽  
Merav Ben Natan ◽  
Joshua Ben-Israel
Keyword(s):  
Adverse Event ◽  
Adverse Events ◽  
Event Management ◽  
Content Type ◽  
Adverse Event Management ◽  
Practical Nurses ◽  
Geriatric Center

Purpose – Adverse events and patient care-related adverse events are a challenging universal problem, among elder residents of geriatric facilities. The aim of this study was to examine which types of adverse events are characteristic of the geriatric center studied and which of the nursing staff reported this event. Design/methodology/approach – Data were retrieved from the computerized adverse event management system at a large geriatric center in central Israel, and all adverse events reported over the past three years were examined. Findings – The study findings indicate that the most common type of adverse event was falls. Older nurses with greater seniority in the facility show a higher tendency to report adverse events. In addition, registered nurses were found to report more often than practical nurses. Practical implications – This study highlights the important role that nurses can play in reporting and reducing adverse events. The role of the nurse is becoming increasingly complex, especially in geriatric facilities, which serve people with complex mental and physical states who are more susceptible to adverse events to begin with. Originality/value – Despite the large number of adverse events, few studies have been undertaken on adverse events in geriatrics in general, and in nursing homes and long-term facilities in particular. Answers to these questions will enable improvement in the quality of care provided and ensure a safe care environment for residents. Systematically examining types of adverse events and the characteristics of those who do and do not report them, can contribute to improvement of processes in the healthcare system in general, and in the facility in particular. Additionally, efficient investigation can improve the behavior of those who enable adverse events.

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

2017 ◽  
Vol 99 (3) ◽  
pp. 199-206 ◽  
Author(s):  
Philippe Moreau ◽  
Meletios A. Dimopoulos ◽  
Paul G. Richardson ◽  
David S. Siegel ◽  
Michele Cavo ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Adverse Event ◽  
Low Dose ◽  
Pooled Analysis ◽  
Event Management ◽  
Refractory Multiple Myeloma ◽  
Adverse Event Management
Sign in / Sign up

Export Citation Format

Share Document